276 related articles for article (PubMed ID: 3753026)
41. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
42. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Canellos GP; Skarin AT; Rosenthal DS; Moloney WC; Frei E
Cancer Treat Rep; 1981; 65 Suppl 1():125-9. PubMed ID: 6173118
[TBL] [Abstract][Full Text] [Related]
43. Recombinant alpha interferon in the treatment of low-grade non-Hodgkin's lymphoma: results of a cooperative phase II trial in 31 patients.
Mantovani L; Guglielmi C; Martelli M; Chierichini A; Deriu L; Sertoli MR; Ardizzoni A; Mandelli F
Haematologica; 1989; 74(6):571-5. PubMed ID: 2628239
[TBL] [Abstract][Full Text] [Related]
44. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
[TBL] [Abstract][Full Text] [Related]
45. Mitoxantrone in malignant lymphoma.
Gams RA; Bryan S; Dukart G; Weiss A; Case D; Jones S; Stein R
Invest New Drugs; 1985; 3(2):219-22. PubMed ID: 4019123
[TBL] [Abstract][Full Text] [Related]
46. [A phase II study of epirubicin in acute leukemia: a cooperative group study].
Sampi K; Masaoka T; Shibata H; Shirakawa S; Kobayashi T; Shirai T; Umeda M; Kozuru M; Sugiyama H; Oguro M
Gan To Kagaku Ryoho; 1986 Aug; 13(8):2594-9. PubMed ID: 3461746
[TBL] [Abstract][Full Text] [Related]
47. [A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
Masaoka T; Oguma S; Shibata H; Nagai K; Horiuchi A; Kitani T; Yonezawa T; Kawagoe H; Yasunaga K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2793-9. PubMed ID: 3753025
[TBL] [Abstract][Full Text] [Related]
48. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
Leiby JM; Unverfurth DV; Neidhart JA
Cancer Treat Rep; 1986 Jul; 70(7):899-901. PubMed ID: 3719583
[TBL] [Abstract][Full Text] [Related]
49. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results.
Cavalli F; Jungi WF; Sonntag RW; Nissen NI; Holland JF
Cancer Treat Rep; 1979; 63(9-10):1599-603. PubMed ID: 227599
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of mitoxantrone in epithelial ovarian cancer.
Lawton F; Blackledge G; Mould J; Latief T; Watson R; Chetiyawardana AD
Cancer Treat Rep; 1987 Jun; 71(6):627-9. PubMed ID: 3581101
[TBL] [Abstract][Full Text] [Related]
53. Mitoxantrone in malignant lymphoma.
Gams RA; Steinberg J; Posner L
Semin Oncol; 1984 Sep; 11(3 Suppl 1):47-9. PubMed ID: 6484580
[TBL] [Abstract][Full Text] [Related]
54. [Late phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
Yamada K; Ohno R; Oguri T; Kamiya O; Yokomaku S; Kobayashi M; Nishiwaki H; Tanaka M; Inagaki J; Mitomo Y
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2447-52. PubMed ID: 1952964
[TBL] [Abstract][Full Text] [Related]
55. Activity of bisantrene in refractory lymphoma.
McLaughlin P; Cabanillas F; Hagemeister FB; Velasquez WS
Cancer Treat Rep; 1987 Jun; 71(6):631-3. PubMed ID: 3581102
[TBL] [Abstract][Full Text] [Related]
56. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
57. Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
Coltman CA; Coltman TM; Balcerzak SP; Morrison FS; Von Hoff DD
Semin Oncol; 1984 Sep; 11(3 Suppl 1):50-3. PubMed ID: 6484581
[TBL] [Abstract][Full Text] [Related]
58. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Arseneau JC; Schoenfeld DA; Borden EC
Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
[TBL] [Abstract][Full Text] [Related]
59. [A phase I study of DWA2114R].
Ariyoshi Y; Wakui A; Hasegawa K; Niitani H; Ogawa M; Sakai Y; Majima H; Furue H; Miyake H; Taguchi T
Gan To Kagaku Ryoho; 1992 May; 19(5):685-93. PubMed ID: 1580642
[TBL] [Abstract][Full Text] [Related]
60. Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Moore JO; Olsen GA
Semin Oncol; 1984 Sep; 11(3 Suppl 1):41-6. PubMed ID: 6385265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
